Rivastigmine, classified as a carbamate-type dual inhibitor of AChE and BuChE, is commonly utilised as a cholinergic agent in the symptomatic management of Alzheimer’s disease; its efficacy and tolerability in this condition were reviewed in a previous study (Spencer and Noble 1998). Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.